| 白 璐,韩 宇.PD-1/PD-L1抑制剂联合小分子抗血管生成药物治疗微卫星稳定性结直肠癌的研究进展[J].肿瘤学杂志,2022,28(2):86-92. |
| PD-1/PD-L1抑制剂联合小分子抗血管生成药物治疗微卫星稳定性结直肠癌的研究进展 |
| Research Progress of PD-1/PD-L1 Inhibitors Combined with Small Molecule Anti-angiogenic Drugs in Treatment of Microsatellite Stable Colorectal Cancer |
| 投稿时间：2022-01-21 |
| DOI：10.11735/j.issn.1671-170X.2022.02.B002 |
|
 |
| 中文关键词: 结直肠癌 免疫治疗 免疫检查点抑制剂 小分子抗血管生成药物 |
| 英文关键词:colorectal cancer immunotherapy immune checkpoint inhibitors small molecule anti-angiogenic |
| 基金项目: |
|
| 摘要点击次数: 999 |
| 全文下载次数: 261 |
| 中文摘要: |
| 摘 要：目前结直肠癌(colorectal cancer，CRC)的治疗以手术、放化疗为主，靶向治疗虽然显著改善了患者预后，但CRC死亡率没有明显降低。近年来，免疫治疗成为肿瘤治疗的新热点，与传统治疗手段相比，免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）治疗在临床试验中展示出较好疗效及耐受。派姆单抗及纳武单抗已被美国FDA批准用于治疗错配修复蛋白缺陷（mismatch-repair-deficient，dMMR）或微卫星高度不稳定性(microsatellite high instability，MSI-H) CRC患者。然而，单药ICIs对于错配修复蛋白正常(mismatch-repair-proficient，pMMR)或微卫星稳定性（microsatellite-stable，MSS）CRC已达到瓶颈，反应率低，无进展生存期和总生存期较差。随着REGONIVO结果显示出良好的疗效，免疫联合小分子抗血管生成药物的治疗模式成为研究热点。全文主要总结PD-1/PD-L1抑制剂联合小分子抗血管生成药物治疗pMMR/MSS CRC的协同机制、研究进展及相关不良反应。 |
| 英文摘要: |
| Abstract： At present， surgery， radiotherapy and chemotherapy are the main treatment methods for colorectal cancer(CRC) patients. Although targeted therapy has significantly improved the prognosis of patients， the mortality of colorectal cancer CRC has not been significantly reduced. In recent years， immunotherapy has become popular for cancer treatment. Compared with traditional treatment， immune checkpoint inhibitors(ICIs) have shown long-term efficacy and tolerance in clinical trials. Pembrolizumab and Nivolumab have been approved by FDA for patients with unresectable or metastatic mismatch-repair-deficient(dMMR) or microsatellite high instability(MSI-H) CRC. However， ICIs have reached the bottleneck for mismatch-repair-proficient(pMMR) or microsatellite-stable(MSS) CRC， with low response rate and poor PFS and OS. With the favourable results of REGONIVO study， the combination of immunotherapy with small-molecule anti-angiogenic drugs has become a hotspot. This article reviews the research progress， synergistic mechanism， and related adverse reactions of PD-1/PD-L1 inhibitors combined with small molecule antiangiogenic drugs in treatment of pMMR/MSS CRC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |